A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2026-10-01

Summary

To learn if evolocumab and nivolumab can control metastatic and refractory renal cell carcinoma. The safety of this drug combination will also be studied.

• Phase: PHASE2

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborators: Bristol-Myers Squibb; Cancer Prevention Research Institute of Texas; United States Department of Defense
• Treatments: evolocumab; Nivolumab